REFERENCES
2. Garmany A, Terzic A. Global healthspan-lifespan gaps among 183 World Health Organization member states. JAMA Netw Open. 2024;7:e2450241.
3. Su B, Luo Y, Zhong P, Zheng X. Long-term trends in healthy and unhealthy life expectancy among adults aged 60 - a global perspective, 1990-2019. China CDC Wkly. 2023;5:877-83.
4. Wang S, Jiang Y, Yang A, Meng F, Zhang J. The expanding burden of neurodegenerative diseases: an unmet medical and social need. Aging Dis. 2024;16:2937-52.
5. Noor A, Zafar S, Zerr I. Neurodegenerative proteinopathies in the proteoform spectrum-tools and challenges. Int J Mol Sci. 2021;22:1085.
7. Stranahan AM, Mattson MP. Bidirectional metabolic regulation of neurocognitive function. Neurobiol Learn Mem. 2011;96:507-16.
8. Procaccini C, Santopaolo M, Faicchia D, et al. Role of metabolism in neurodegenerative disorders. Metabolism. 2016;65:1376-90.
9. Shinohara M, Sato N. Bidirectional interactions between diabetes and Alzheimer’ disease. Neurochem Int. 2017;108:296-302.
10. Muddapu VR, Dharshini SAP, Chakravarthy VS, Gromiha MM. Neurodegenerative diseases - is metabolic deficiency the root cause? Front Neurosci. 2020;14:213.
11. Song D, Li Y, Yang LL, Luo YX, Yao XQ. Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface. Mol Neurodegener. 2025;20:61.
12. Kaya E, Yılmaz Y. Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: a comprehensive review. Turk J Gastroenterol. 2024;35:76-82.
13. Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565-81.
14. Palmer AK, Jensen MD. Metabolic changes in aging humans: current evidence and therapeutic strategies. J Clin Invest. 2022;132:e158451.
15. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186:243-78.
16. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-217.
17. Niedernhofer LJ, Gurkar AU, Wang Y, Vijg J, Hoeijmakers JHJ, Robbins PD. Nuclear genomic instability and aging. Annu Rev Biochem. 2018;87:295-322.
18. Shadfar S, Brocardo M, Atkin JD. The complex mechanisms by which neurons die following DNA damage in neurodegenerative diseases. Int J Mol Sci. 2022;23:2484.
19. Welch G, Tsai LH. Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease. EMBO Rep. 2022;23:e54217.
20. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem. 2005;93:953-62.
21. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer’s disease. Antioxid Redox Signal. 2006;8:2039-45.
22. Bradley-Whitman MA, Timmons MD, Beckett TL, Murphy MP, Lynn BC, Lovell MA. Nucleic acid oxidation: an early feature of Alzheimer’s disease. J Neurochem. 2014;128:294-304.
23. Santos RX, Correia SC, Zhu X, et al. Nuclear and mitochondrial DNA oxidation in Alzheimer’s disease. Free Radic Res. 2012;46:565-76.
24. Fukae J, Takanashi M, Kubo S, et al. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson’s disease and related neurodegenerative disorders. Acta Neuropathol. 2005;109:256-62.
25. Shimizu I, Yoshida Y, Suda M, Minamino T. DNA damage response and metabolic disease. Cell Metab. 2014;20:967-77.
26. Włodarczyk M, Nowicka G. Obesity, DNA damage, and development of obesity-related diseases. Int J Mol Sci. 2019;20:1146.
27. Włodarczyk M, Jabłonowska-Lietz B, Olejarz W, Nowicka G. Anthropometric and dietary factors as predictors of DNA damage in obese women. Nutrients. 2018;10:578.
28. Scarpato R, Verola C, Fabiani B, Bianchi V, Saggese G, Federico G. Nuclear damage in peripheral lymphocytes of obese and overweight Italian children as evaluated by the gamma-H2AX focus assay and micronucleus test. FASEB J. 2011;25:685-93.
29. Zhong A, Chang M, Yu T, et al. Aberrant DNA damage response and DNA repair pathway in high glucose conditions. J Can Res Updates. 2018;7:64-74.
30. Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules. 2022;12:542.
31. Stopper H, Schinzel R, Sebekova K, Heidland A. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 2003;190:151-6.
32. Bhattacharya R, Alam MR, Kamal MA, Seo KJ, Singh LR. AGE-RAGE axis culminates into multiple pathogenic processes: a central road to neurodegeneration. Front Mol Neurosci. 2023;16:1155175.
33. Alanazi AFR, Parkinson GN, Haider S. Structural motifs at the telomeres and their role in regulatory pathways. Biochemistry. 2024;63:827-42.
34. Harman A, Bryan TM. Telomere maintenance and the DNA damage response: a paradoxical alliance. Front Cell Dev Biol. 2024;12:1472906.
35. Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: state-of-the-art, open issues, and future perspectives. Front Genet. 2020;11:630186.
36. Levstek T, Kozjek E, Dolžan V, Trebušak Podkrajšek K. Telomere attrition in neurodegenerative disorders. Front Cell Neurosci. 2020;14:219.
37. Forero DA, González-Giraldo Y, López-Quintero C, Castro-Vega LJ, Barreto GE, Perry G. Meta-analysis of telomere length in Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2016;71:1069-73.
38. Hackenhaar FS, Josefsson M, Adolfsson AN, et al. Short leukocyte telomeres predict 25-year Alzheimer’s disease incidence in non-APOE ε4-carriers. Alzheimers Res Ther. 2021;13:130.
39. Cui Y, Gao YT, Cai Q, et al. Associations of leukocyte telomere length with body anthropometric indices and weight change in Chinese women. Obesity. 2013;21:2582-8.
40. Gielen M, Hageman GJ, Antoniou EE, et al; TELOMAAS group. Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies. Am J Clin Nutr. 2018;108:453-75.
41. Xia J, Xu L, Yu Y, et al. Associations between weight-adjusted-waist index and telomere length: results from NHANES: an observational study. Medicine. 2024;103:e37905.
42. Batsis JA, Mackenzie TA, Vasquez E, et al. Association of adiposity, telomere length and mortality: data from the NHANES 1999-2002. Int J Obes. 2018;42:198-204.
43. Tzanetakou IP, Katsilambros NL, Benetos A, Mikhailidis DP, Perrea DN. “Is obesity linked to aging? Ageing Res Rev. 2012;11:220-9.
44. He X, Cao L, Fu X, et al. The association between telomere length and diabetes mellitus: accumulated evidence from observational studies. J Clin Endocrinol Metab. 2024;110:e177-85.
46. Słowikowski B, Owecki W, Jeske J, et al. Epigenetics and the neurodegenerative process. Epigenomics. 2024;16:473-91.
47. Liu Y, Wang M, Marcora EM, Zhang B, Goate AM. Promoter DNA hypermethylation - implications for Alzheimer’s disease. Neurosci Lett. 2019;711:134403.
48. Yu CC, Jiang T, Yang AF, Du YJ, Wu M, Kong LH. Epigenetic modulation on Tau phosphorylation in Alzheimer’s disease. Neural Plast. 2019;2019:6856327.
49. Ma Y, Wang W, Liu S, et al. Epigenetic regulation of neuroinflammation in Alzheimer’s disease. Cells. 2023;13:79.
50. Park J, Lee K, Kim K, Yi SJ. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther. 2022;7:217.
51. Balmik AA, Chinnathambi S. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer’s disease. Cell Commun Signal. 2021;19:51.
52. Jung BC, Kang S. Epigenetic regulation of inflammatory factors in adipose tissue. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866:159019.
53. Ling C, Bacos K, Rönn T. Epigenetics of type 2 diabetes mellitus and weight change - a tool for precision medicine? Nat Rev Endocrinol. 2022;18:433-48.
54. Franzago M, Pilenzi L, Di Rado S, Vitacolonna E, Stuppia L. The epigenetic aging, obesity, and lifestyle. Front Cell Dev Biol. 2022;10:985274.
55. Meyers AK, Zhu X. The NLRP3 inflammasome: metabolic regulation and contribution to inflammaging. Cells. 2020;9:1808.
56. La Rosa F, Mancuso R, Agostini S, et al. Pharmacological and epigenetic regulators of NLRP3 inflammasome activation in Alzheimer’s disease. Pharmaceuticals. 2021;14:1187.
57. Lu S, Li Y, Qian Z, et al. Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front Immunol. 2023;14:1052756.
58. Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018;19:610-21.
59. Coppedè F. Mitochondrial DNA methylation and mitochondria-related epigenetics in neurodegeneration. Neural Regen Res. 2024;19:405-6.
60. Low HC, Chilian WM, Ratnam W, et al. Changes in mitochondrial epigenome in type 2 diabetes mellitus. Br J Biomed Sci. 2023;80:10884.
61. Maldonado-Lasuncion I, Atienza M, Sanchez-Espinosa MP, Cantero JL. Aging-related changes in cognition and cortical integrity are associated with serum expression of candidate microRNAs for Alzheimer disease. Cereb Cortex. 2019;29:4426-37.
62. Shen Y, Xu H, Pan X, et al. miR-34a and miR-125b are upregulated in peripheral blood mononuclear cells from patients with type 2 diabetes mellitus. Exp Ther Med. 2017;14:5589-96.
63. Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 2019;20:421-35.
64. Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217:51-63.
65. Kurtishi A, Rosen B, Patil KS, Alves GW, Møller SG. Cellular proteostasis in neurodegeneration. Mol Neurobiol. 2019;56:3676-89.
66. Rao G, Croft B, Teng C, Awasthi V. Ubiquitin-proteasome system in neurodegenerative disorders. J Drug Metab Toxicol. 2015;6:187.
67. Ottens F, Franz A, Hoppe T. Build-UPS and break-downs: metabolism impacts on proteostasis and aging. Cell Death Differ. 2021;28:505-21.
68. Queisser MA, Yao D, Geisler S, et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes. 2010;59:670-8.
69. James HA, O’Neill BT, Nair KS. Insulin regulation of proteostasis and clinical implications. Cell Metab. 2017;26:310-23.
70. Santiago-Lopez AJ, Berglund K, Gross RE, Gutekunst CN. Kinetic monitoring of neuronal stress response to proteostasis dysfunction. Mol Cell Neurosci. 2022;118:103682.
71. Moll L, Ben-Gedalya T, Reuveni H, Cohen E. The inhibition of IGF-1 signaling promotes proteostasis by enhancing protein aggregation and deposition. FASEB J. 2016;30:1656-69.
72. Höhn A, Tramutola A, Cascella R. Proteostasis failure in neurodegenerative diseases: focus on oxidative stress. Oxid Med Cell Longev. 2020;2020:5497046.
73. Ross JM, Olson L, Coppotelli G. Mitochondrial and ubiquitin proteasome system dysfunction in ageing and disease: two sides of the same coin? Int J Mol Sci. 2015;16:19458-76.
74. Ahmed T, Zulfiqar A, Arguelles S, et al. Map kinase signaling as therapeutic target for neurodegeneration. Pharmacol Res. 2020;160:105090.
75. Sonninen TM, Goldsteins G, Laham-Karam N, Koistinaho J, Lehtonen Š. Proteostasis disturbances and inflammation in neurodegenerative diseases. Cells. 2020;9:2183.
76. Chen Y, Qin Q, Zhao W, et al. Carnosol reduced pathogenic protein aggregation and cognitive impairment in neurodegenerative diseases models via improving proteostasis and ameliorating mitochondrial disorders. J Agric Food Chem. 2022;70:10490-505.
77. Saha S, Panigrahi DP, Patil S, Bhutia SK. Autophagy in health and disease: a comprehensive review. Biomed Pharmacother. 2018;104:485-95.
78. Mokarram P, Ghavami S. Autophagy unveiled: new horizons in health and disease. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167289.
79. Ryter SW, Cloonan SM, Choi AM. Autophagy: a critical regulator of cellular metabolism and homeostasis. Mol Cells. 2013;36:7-16.
80. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol. 2018;28:3-13.
81. Park H, Kang JH, Lee S. Autophagy in neurodegenerative diseases: a hunter for aggregates. Int J Mol Sci. 2020;21:3369.
82. Long Z, Chen J, Zhao Y, et al. Dynamic changes of autophagic flux induced by Abeta in the brain of postmortem Alzheimer’s disease patients, animal models and cell models. Aging. 2020;12:10912-30.
83. Jiang S, Bhaskar K. Degradation and transmission of tau by autophagic-endolysosomal networks and potential therapeutic targets for tauopathy. Front Mol Neurosci. 2020;13:586731.
84. Palmer JE, Wilson N, Son SM, et al. Autophagy, aging, and age-related neurodegeneration. Neuron. 2025;113:29-48.
86. Menikdiwela KR, Ramalingam L, Rasha F, et al. Autophagy in metabolic syndrome: breaking the wheel by targeting the renin-angiotensin system. Cell Death Dis. 2020;11:87.
87. Namkoong S, Cho CS, Semple I, Lee JH. Autophagy dysregulation and obesity-associated pathologies. Mol Cells. 2018;41:3-10.
88. Zhao X, Chen Y, Tan X, et al. Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB. J Pathol. 2018;245:235-48.
89. de Mello NP, Orellana AM, Mazucanti CH, de Morais Lima G, Scavone C, Kawamoto EM. Insulin and autophagy in neurodegeneration. Front Neurosci. 2019;13:491.
90. Lan ZQ, Ge ZY, Lv SK, Zhao B, Li CX. The regulatory role of lipophagy in central nervous system diseases. Cell Death Discov. 2023;9:229.
91. Haidar M, Loix M, Bogie JFJ, Hendriks JJA. Lipophagy: a new player in CNS disorders. Trends Endocrinol Metab. 2021;32:941-51.
92. Park K, Lee MS. Current status of autophagy enhancers in metabolic disorders and other diseases. Front Cell Dev Biol. 2022;10:811701.
93. Rahman MA, Rhim H. Therapeutic implication of autophagy in neurodegenerative diseases. BMB Rep. 2017;50:345-54.
97. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316-38.
98. de la Monte SM, Tong M. Dysregulated mTOR networks in experimental sporadic Alzheimer’s disease. Front Cell Neurosci. 2024;18:1432359.
99. Fernandez F, Griffiths LR, Sutherland HG, et al. Sirtuin proteins and memory: a promising target in Alzheimer’s disease therapy? Nutrients. 2024;16:4088.
101. Maldonado-Rojas ADC, Zuarth-Vázquez JM, Uribe M, Barbero-Becerra VJ. Insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD): pathways of action of hypoglycemic agents. Ann Hepatol. 2024;29:101182.
103. Arab Sadeghabadi Z, Nourbakhsh M, Pasalar P, et al. Reduced gene expression of sirtuins and active AMPK levels in children and adolescents with obesity and insulin resistance. Obes Res Clin Pract. 2018;12:167-73.
104. Folch J, Olloquequi J, Ettcheto M, et al. The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front Aging Neurosci. 2019;11:236.
105. Davoody S, Asgari Taei A, Khodabakhsh P, Dargahi L. mTOR signaling and Alzheimer’s disease: what we know and where we are? CNS Neurosci Ther. 2024;30:e14463.
106. Marinangeli C, Didier S, Vingtdeux V. AMPK in neurodegenerative diseases: implications and therapeutic perspectives. Curr Drug Targets. 2016;17:890-907.
107. Johnson ML, Distelmaier K, Lanza IR, et al. Mechanism by which caloric restriction improves insulin sensitivity in sedentary obese adults. Diabetes. 2016;65:74-84.
108. Ma L, Dong W, Wang R, et al. Effect of caloric restriction on the SIRT1/mTOR signaling pathways in senile mice. Brain Res Bull. 2015;116:67-72.
109. Cantó C, Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology. 2011;26:214-24.
110. Dos Santos C, Cambraia A, Shrestha S, et al. Calorie restriction increases insulin sensitivity to promote beta cell homeostasis and longevity in mice. Nat Commun. 2024;15:9063.
111. Hansen B, Roomp K, Ebid H, Schneider JG. Perspective: the impact of fasting and caloric restriction on neurodegenerative diseases in humans. Adv Nutr. 2024;15:100197.
114. Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis. Alzheimers Dement. 2023;19:333-42.
115. Bhatia S, Rawal R, Sharma P, Singh T, Singh M, Singh V. Mitochondrial dysfunction in Alzheimer’s disease: opportunities for drug development. Curr Neuropharmacol. 2022;20:675-92.
116. Højlund K, Mogensen M, Sahlin K, Beck-Nielsen H. Mitochondrial dysfunction in type 2 diabetes and obesity. Endocrinol Metab Clin North Am. 2008;37:713-31, x.
117. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17:446-52.
118. Yoon Y, Galloway CA, Jhun BS, Yu T. Mitochondrial dynamics in diabetes. Antioxid Redox Signal. 2011;14:439-57.
119. Lin J, Zhang X, Sun Y, et al. Exercise ameliorates muscular excessive mitochondrial fission, insulin resistance and inflammation in diabetic rats via irisin/AMPK activation. Sci Rep. 2024;14:10658.
120. Sridharan PS, Koh Y, Miller E, et al. Acutely blocking excessive mitochondrial fission prevents chronic neurodegeneration after traumatic brain injury. Cell Rep Med. 2024;5:101715.
121. Belosludtsev KN, Belosludtseva NV, Dubinin MV. Diabetes mellitus, mitochondrial dysfunction and Ca2+-dependent permeability transition pore. Int J Mol Sci. 2020;21:6559.
122. Kalani K, Yan SF, Yan SS. Mitochondrial permeability transition pore: a potential drug target for neurodegeneration. Drug Discov Today. 2018;23:1983-9.
123. Gurung P, Lukens JR, Kanneganti TD. Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med. 2015;21:193-201.
124. Rovira-Llopis S, Apostolova N, Bañuls C, Muntané J, Rocha M, Victor VM. Mitochondria, the NLRP3 inflammasome, and sirtuins in type 2 diabetes: new therapeutic targets. Antioxid Redox Signal. 2018;29:749-91.
125. Litwiniuk A, Baranowska-Bik A, Domańska A, Kalisz M, Bik W. Contribution of mitochondrial dysfunction combined with NLRP3 inflammasome activation in selected neurodegenerative diseases. Pharmaceuticals. 2021;14:1221.
126. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124.
127. Cortés-Rojo C, Vargas-Vargas MA. Don’t give up on mitochondria as a target for the treatment of diabetes and its complications. World J Diabetes. 2024;15:2015-21.
128. Fields M, Marcuzzi A, Gonelli A, Celeghini C, Maximova N, Rimondi E. Mitochondria-targeted antioxidants, an innovative class of antioxidant compounds for neurodegenerative diseases: perspectives and limitations. Int J Mol Sci. 2023;24:3739.
129. Ding W, Yang X, Lai K, Jiang Y, Liu Y. The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus. Arch Pharm Res. 2024;47:219-48.
130. Uittenbogaard M, Chiaramello A. Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des. 2014;20:5574-93.
131. Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813-27.
132. Di Micco R, Krizhanovsky V, Baker D, d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021;22:75-95.
133. Wang B, Han J, Elisseeff JH, Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024;25:958-78.
134. Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A. Role of p53 in the regulation of cellular senescence. Biomolecules. 2020;10:420.
135. Alshaebi F, Sciortino A, Kayed R. The role of glial cell senescence in Alzheimer’s disease. J Neurochem. 2025;169:e70051.
136. Zhu J, Wu C, Yang L. Cellular senescence in Alzheimer’s disease: from physiology to pathology. Transl Neurodegener. 2024;13:55.
137. Shen QQ, Jv XH, Ma XZ, et al. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson’s disease. Acta Pharmacol Sin. 2024;45:268-81.
138. Lee S, Wang EY, Steinberg AB, Walton CC, Chinta SJ, Andersen JK. A guide to senolytic intervention in neurodegenerative disease. Mech Ageing Dev. 2021;200:111585.
139. Zhang H, Zhou H, Shen X, et al. The role of cellular senescence in metabolic diseases and the potential for senotherapeutic interventions. Front Cell Dev Biol. 2023;11:1276707.
140. Arias C, Álvarez-Indo J, Cifuentes M, Morselli E, Kerr B, Burgos PV. Enhancing adipose tissue functionality in obesity: senotherapeutics, autophagy and cellular senescence as a target. Biol Res. 2024;57:51.
141. Palmer AK, Xu M, Zhu Y, et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell. 2019;18:e12950.
142. Narasimhan A, Flores RR, Robbins PD, Niedernhofer LJ. Role of cellular senescence in type II diabetes. Endocrinology. 2021;162:bqab136.
143. Murakami T, Inagaki N, Kondoh H. Cellular senescence in diabetes mellitus: distinct senotherapeutic strategies for adipose tissue and pancreatic β cells. Front Endocrinol. 2022;13:869414.
144. Ghosh P, Fontanella RA, Scisciola L, et al. Obesity-induced neuronal senescence: unraveling the pathophysiological links. Ageing Res Rev. 2024;101:102533.
145. Cleland NRW, Al-Juboori SI, Dobrinskikh E, Bruce KD. Altered substrate metabolism in neurodegenerative disease: new insights from metabolic imaging. J Neuroinflammation. 2021;18:248.
146. Han X, Lei Q, Xie J, et al. Potential regulators of the senescence-associated secretory phenotype during senescence and aging. J Gerontol A Biol Sci Med Sci. 2022;77:2207-18.
147. Rando TA, Jones DL. Regeneration, rejuvenation, and replacement: turning back the clock on tissue aging. Cold Spring Harb Perspect Biol. 2021;13:a040907.
148. Rezazadeh S, Ellison-Hughes GM. Editorial: stem cell exhaustion in aging. Front Aging. 2024;5:1433702.
149. Brunet A, Goodell MA, Rando TA. Ageing and rejuvenation of tissue stem cells and their niches. Nat Rev Mol Cell Biol. 2023;24:45-62.
150. Iqbal MA, Bilen M, Liu Y, et al. The integrated stress response promotes neural stem cell survival under conditions of mitochondrial dysfunction in neurodegeneration. Aging Cell. 2024;23:e14165.
151. Scopa C, Marrocco F, Latina V, et al. Impaired adult neurogenesis is an early event in Alzheimer’s disease neurodegeneration, mediated by intracellular Aβ oligomers. Cell Death Differ. 2020;27:934-48.
152. Al-Regaiey K. Crosstalk between adipogenesis and aging: role of polyphenols in combating adipogenic-associated aging. Immun Ageing. 2024;21:76.
153. Chen X, Shen WB, Yang P, Dong D, Sun W, Yang P. High glucose inhibits neural stem cell differentiation through oxidative stress and endoplasmic reticulum stress. Stem Cells Dev. 2018;27:745-55.
154. Hidaka R, Machida M, Fujimaki S, Terashima K, Asashima M, Kuwabara T. Monitoring neurodegeneration in diabetes using adult neural stem cells derived from the olfactory bulb. Stem Cell Res Ther. 2013;4:51.
155. Geroldi D, Minoretti P, Emanuele E. Brain-derived neurotrophic factor and the metabolic syndrome: more than just a hypothesis. Med Hypotheses. 2006;67:195-6.
156. Motamedi S, Karimi I, Jafari F. The interrelationship of metabolic syndrome and neurodegenerative diseases with focus on brain-derived neurotrophic factor (BDNF): kill two birds with one stone. Metab Brain Dis. 2017;32:651-65.
157. Islam O, Loo TX, Heese K. Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res. 2009;6:42-53.
158. Navarro Negredo P, Yeo RW, Brunet A. Aging and rejuvenation of neural stem cells and their niches. Cell Stem Cell. 2020;27:202-23.
159. Marsh SE, Blurton-Jones M. Neural stem cell therapy for neurodegenerative disorders: the role of neurotrophic support. Neurochem Int. 2017;106:94-100.
160. Zomer HD, Vidane AS, Gonçalves NN, Ambrósio CE. Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives. Stem Cells Cloning. 2015;8:125-34.
161. Sun H, Xia T, Ma S, Lv T, Li Y. Intercellular communication is crucial in the regulation of healthy aging via exosomes. Pharmacol Res. 2025;212:107591.
162. Fafián-Labora JA, O’Loghlen A. Classical and nonclassical intercellular communication in senescence and ageing. Trends Cell Biol. 2020;30:628-39.
163. Sigdel S, Swenson S, Wang J. Extracellular vesicles in neurodegenerative diseases: an update. Int J Mol Sci. 2023;24:13161.
164. Aas V, Øvstebø R, Brusletto BS, et al. Distinct microRNA and protein profiles of extracellular vesicles secreted from myotubes from morbidly obese donors with type 2 diabetes in response to electrical pulse stimulation. Front Physiol. 2023;14:1143966.
165. Liu W, Liu T, Zhao Q, Ma J, Jiang J, Shi H. Adipose tissue-derived extracellular vesicles: a promising biomarker and therapeutic strategy for metabolic disorders. Stem Cells Int. 2023;2023:9517826.
166. Park KJ, Gao Y. Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials. Front Neurosci. 2024;18:1481390.
167. Liu X, Shen L, Wan M, Xie H, Wang Z. Peripheral extracellular vesicles in neurodegeneration: pathogenic influencers and therapeutic vehicles. J Nanobiotechnology. 2024;22:170.
168. Kumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9:27.
169. Shive C, Pandiyan P. Inflammation, immune senescence, and dysregulated immune regulation in the elderly. Front Aging. 2022;3:840827.
170. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8:267.
171. Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024;16:1347987.
172. Lista S, Imbimbo BP, Grasso M, et al. Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches? J Neuroinflammation. 2024;21:187.
173. Singh J, Habean ML, Panicker N. Inflammasome assembly in neurodegenerative diseases. Trends Neurosci. 2023;46:814-31.
174. Welikovitch LA, Do Carmo S, Maglóczky Z, et al. Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc Natl Acad Sci U S A. 2020;117:6844-54.
175. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320:C375-91.
176. Li H, Meng Y, He S, et al. Macrophages, chronic inflammation, and insulin resistance. Cells. 2022;11:3001.
177. Mirabelli M, Misiti R, Sicilia L, et al. Hypoxia in human obesity: new insights from inflammation towards insulin resistance-a narrative review. Int J Mol Sci. 2024;25:9802.
178. Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57:2099-114.
179. Cao SS, Luo KL, Shi L. Endoplasmic reticulum stress interacts with inflammation in human diseases. J Cell Physiol. 2016;231:288-94.
180. Gkrinia EMM, Belančić A. The mechanisms of chronic inflammation in obesity and potential therapeutic strategies: a narrative review. Curr Issues Mol Biol. 2025;47:357.
181. Elwood E, Lim Z, Naveed H, Galea I. The effect of systemic inflammation on human brain barrier function. Brain Behav Immun. 2017;62:35-40.
182. Dukhinova M, Kuznetsova I, Kopeikina E, et al. Platelets mediate protective neuroinflammation and promote neuronal plasticity at the site of neuronal injury. Brain Behav Immun. 2018;74:7-27.
183. Sagar RC, Ajjan RA, Naseem KM. Non-traditional pathways for platelet pathophysiology in diabetes: implications for future therapeutic targets. Int J Mol Sci. 2022;23:4973.
184. Wu KK, Cheung SW, Cheng KK. NLRP3 inflammasome activation in adipose tissues and its implications on metabolic diseases. Int J Mol Sci. 2020;21:4184.
185. Wree A, Eguchi A, McGeough MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898-910.
186. Hanslik KL, Ulland TK. The role of microglia and the Nlrp3 inflammasome in Alzheimer’s disease. Front Neurol. 2020;11:570711.
187. Domingo E, Marques P, Francisco V, Piqueras L, Sanz MJ. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases? Pharmacol Res. 2024;200:107058.
188. Mohamed W, Kumar J, Alghamdi BS, Soliman AH, Toshihide Y. Neurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives. IBRO Neurosci Rep. 2023;14:95-110.
189. Haran JP, McCormick BA. Aging, frailty, and the microbiome-how dysbiosis influences human aging and disease. Gastroenterology. 2021;160:507-23.
190. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330-9.
191. Wu YL, Xu J, Rong XY, Wang F, Wang HJ, Zhao C. Gut microbiota alterations and health status in aging adults: from correlation to causation. Aging Med. 2021;4:206-13.
193. Intili G, Paladino L, Rappa F, et al. From dysbiosis to neurodegenerative diseases through different communication pathways: an overview. Biology. 2023;12:195.
194. Lista S, Munafò A, Caraci F, et al. Gut microbiota in Alzheimer’s disease: understanding molecular pathways and potential therapeutic perspectives. Ageing Res Rev. 2025;104:102659.
195. Ahmed H, Leyrolle Q, Koistinen V, et al. Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes. 2022;14:2102878.
196. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7:27.
197. Bandopadhyay P, Ganguly D. Gut dysbiosis and metabolic diseases. Prog Mol Biol Transl Sci. 2022;191:153-74.
198. Chanda D, De D. Meta-analysis reveals obesity associated gut microbial alteration patterns and reproducible contributors of functional shift. Gut Microbes. 2024;16:2304900.
199. Fan S, Chen S, Lin L. Research progress of gut microbiota and obesity caused by high-fat diet. Front Cell Infect Microbiol. 2023;13:1139800.
200. Clemente-Postigo M, Oliva-Olivera W, Coin-Aragüez L, et al. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. Am J Physiol Endocrinol Metab. 2019;316:E319-32.
201. Tang W, Zhu H, Feng Y, Guo R, Wan D. The impact of gut microbiota disorders on the blood-brain barrier. Infect Drug Resist. 2020;13:3351-63.
202. Zhang D, Jian YP, Zhang YN, et al. Short-chain fatty acids in diseases. Cell Commun Signal. 2023;21:212.
203. Zhang M, Zhou C, Li X, et al. Interactions between gut microbiota, host circadian rhythms, and metabolic diseases. Adv Nutr. 2025;16:100416.
204. Hablitz LM, Plá V, Giannetto M, et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun. 2020;11:4411.
205. Yoo JY, Kim SS. Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients. 2016;8:173.
206. Ojha S, Patil N, Jain M, Kole C, Kaushik P. Probiotics for neurodegenerative diseases: a systemic review. Microorganisms. 2023;11:1083.
207. Zheng L, Ji YY, Wen XL, Duan SL. Fecal microbiota transplantation in the metabolic diseases: current status and perspectives. World J Gastroenterol. 2022;28:2546-60.
208. Matheson JT, Holsinger RMD. The role of fecal microbiota transplantation in the treatment of neurodegenerative diseases: a review. Int J Mol Sci. 2023;24:1001.
209. Freude KK, Moreno-Gonzalez I, Rodriguez-Ortiz CJ, Baglietto-Vargas D. Editorial: metabolic alterations in neurodegenerative disorders. Front Aging Neurosci. 2022;14:833109.
210. de Araújo Boleti AP, de Oliveira Flores TM, Moreno SE, Anjos LD, Mortari MR, Migliolo L. Neuroinflammation: an overview of neurodegenerative and metabolic diseases and of biotechnological studies. Neurochem Int. 2020;136:104714.
211. Mullins RJ, Diehl TC, Chia CW, Kapogiannis D. Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci. 2017;9:118.
212. Komleva Y, Chernykh A, Lopatina O, et al. Inflamm-aging and brain insulin resistance: new insights and role of life-style strategies on cognitive and social determinants in aging and neurodegeneration. Front Neurosci. 2020;14:618395.
213. Surguchov A. Caveolin: a new link between diabetes and AD. Cell Mol Neurobiol. 2020;40:1059-66.
214. Jinesh S, Özüpek B, Aditi P. Premature aging and metabolic diseases: the impact of telomere attrition. Front Aging. 2025;6:1541127.
215. Silberman DM. Metabolism, neurodegeneration and epigenetics: emerging role of Sirtuins. Neural Regen Res. 2018;13:417-8.
216. Bagherniya M, Butler AE, Barreto GE, Sahebkar A. The effect of fasting or calorie restriction on autophagy induction: a review of the literature. Ageing Res Rev. 2018;47:183-97.
217. Fontana L, Ghezzi L, Cross AH, Piccio L. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. J Exp Med. 2021;218:e20190086.
218. Kruczkowska W, Gałęziewska J, Buczek P, Płuciennik E, Kciuk M, Śliwińska A. Overview of metformin and neurodegeneration: a comprehensive review. Pharmaceuticals. 2025;18:486.
219. Nah J, Yuan J, Jung YK. Autophagy in neurodegenerative diseases: from mechanism to therapeutic approach. Mol Cells. 2015;38:381-9.
220. Guerville F, De Souto Barreto P, Ader I, et al. Revisiting the hallmarks of aging to identify markers of biological age. J Prev Alzheimers Dis. 2020;7:56-64.
221. Hampel H, Nisticò R, Seyfried NT, et al; Alzheimer Precision Medicine Initiative (APMI). Omics sciences for systems biology in Alzheimer’s disease: state-of-the-art of the evidence. Ageing Res Rev. 2021;69:101346.
222. Santoro A, Martucci M, Conte M, Capri M, Franceschi C, Salvioli S. Inflammaging, hormesis and the rationale for anti-aging strategies. Ageing Res Rev. 2020;64:101142.
223. James DL, Hawley NA, Mohr AE, et al. Impact of intermittent fasting and/or caloric restriction on aging-related outcomes in adults: a scoping review of randomized controlled trials. Nutrients. 2024;16:316.
224. Garatachea N, Pareja-Galeano H, Sanchis-Gomar F, et al. Exercise attenuates the major hallmarks of aging. Rejuvenation Res. 2015;18:57-89.
225. Poljšak B, Kovač V, Špalj S, Milisav I. The central role of the NAD+ molecule in the development of aging and the prevention of chronic age-related diseases: strategies for NAD+ modulation. Int J Mol Sci. 2023;24:2959.
226. Imb M, Véghelyi Z, Maurer M, Kühnel H. Exploring senolytic and senomorphic properties of medicinal plants for anti-aging therapies. Int J Mol Sci. 2024;25:10419.
227. Liu SZ, Chiao YA, Rabinovitch PS, Marcinek DJ. Mitochondrial targeted interventions for aging. Cold Spring Harb Perspect Med. 2024;14:a041199.
228. Trisal A, Singh AK. Clinical insights on caloric restriction mimetics for mitigating brain aging and related neurodegeneration. Cell Mol Neurobiol. 2024;44:67.
229. Barthet VJA, Lowe SW. Killing wisely: precision senolytics in the age of frailty. Genes Dev. 2025;39:910-3.
